---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-003766"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2026-05-13T12:05:18+00:00"
generated_at: "2026-05-13T12:17:39.315513+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences Q1 2026 net loss down 49% to $0.5M; royalty revenue up 36% to $0.8M

## Summary
- Net loss of $0.5M ($0.04 per share) vs $0.9M a year ago; cash $7.3M at March 31, 2026.
- Royalty revenue $0.8M (+36% YoY) primarily from Takeda sublicense agreement.
- R&D expenses $0.7M (-25% YoY) due to lower preclinical costs; G&A $0.6M, flat.
- DNase I platform progress: translational data, manufacturing readiness, Israeli Ministry of Health approval for CAR T study.
- Company continuing evaluation of strategic alternatives to maximize shareholder value.

## SEC filing metadata
- accession: 0001683168-26-003766
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2026-05-13T12:05:18+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316826003766/0001683168-26-003766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316826003766/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-003766
- JSON: https://secwatch.observer/filing/0001683168-26-003766.json
- Plain text: https://secwatch.observer/filing/0001683168-26-003766.txt

## Key facts
- Earnings Releases
  Xenetic Biosciences, Inc. reported the three months ended March 31, 2026 results: revenue approximately $0.8 million, net income approximately $0.5 million.
  - Period: the three months ended March 31, 2026
  - Revenue: approximately $0.8 million
  - Net income: approximately $0.5 million
  - Result: reported results
  source text: Royalty revenue for the three months ended March 31, 2026 increased approximately 36% to approximately $0.8 million, compared to approximately $0.6 million for the comparable prior year period, primarily driven by increased royalty payments recognized under the Company’s sublicense agreement with Takeda Pharmaceuticals Co. Ltd.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316826003766/0001683168-26-003766-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.